Cited by 206Nuclear Structure and FunctionLung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.

XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer

Open access

Kim, Jimi, McMillan, Elizabeth, Kim, Hyun Seok, Venkateswaran, Niranjan, Makkar, Gurbani, Rodriguez-Canales, Jaime, Villalobos, Pamela, Neggers, Jasper Edgar, Mendiratta, Saurabh, Wei, Shuguang, Landesman, Yosef, Senapedis, William, Baloglu, Erkan, Chow, Chi-Wan B., Frink, Robin E., Gao, Boning, Roth, Michael, Minna, John D., Daelemans, Dirk, Wistuba, Ignacio I., Posner, Bruce A., Scaglioni, Pier Paolo, White, Michael A.·2016·Nature

DOI 10.1038/nature19771PMC PMC5161658

Open this paper in CoChat — free account

Abstract

The common participation of oncogenic KRAS proteins in many of the most lethal human cancers, together with the ease of detecting somatic KRAS mutant alleles in patient samples, has spurred persistent and intensive efforts to develop drugs that inhibit KRAS activity. However, advances have been hindered by the pervasive inter- and intra-lineage diversity in the targetable mechanisms that underlie KRAS-driven cancers, limited pharmacological accessibility of many candidate synthetic-lethal interactions and the swift emergence of unanticipated resistance mechanisms to otherwise effective targeted therapies. Here we demonstrate the acute and specific cell-autonomous addiction of KRAS-mutant non-small-cell lung cancer cells to receptor-dependent nuclear export. A multi-genomic, data-driven approach, utilizing 106 human non-small-cell lung cancer cell lines, was used to interrogate 4,725 biological processes with 39,760 short interfering RNA pools for those selectively required for the survival of KRAS-mutant cells that harbour a broad spectrum of phenotypic variation. Nuclear transport machinery was the sole process-level discriminator of statistical significance. Chemical perturbation of the nuclear export receptor XPO1 (also known as CRM1), with a clinically available drug, revealed a robust synthetic-lethal interaction with native or engineered oncogenic KRAS both in vitro and in vivo. The primary mechanism underpinning XPO1 inhibitor sensitivity was intolerance to the accumulation of nuclear IκBα (also known as NFKBIA), with consequent inhibition of NFκB transcription factor activity. Intrinsic resistance associated with concurrent FSTL5 mutations was detected and determined to be a consequence of YAP1 activation via a previously unappreciated FSTL5-Hippo pathway regulatory axis. This occurs in approximately 17% of KRAS-mutant lung cancers, and can be overcome with the co-administration of a YAP1-TEAD inhibitor. These findings indicate that clinically available XPO1 inhibitors are a promising therapeutic strategy for a considerable cohort of patients with lung cancer when coupled to genomics-guided patient selection and observation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature19771

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Clustering by Passing Messages Between Data Points
Frey, B. J., & Dueck, D. (2007) · Science · doi:10.1126/science.1136800 · Cited by 6,855
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Self-citation
Hippo pathway in organ size control, tissue homeostasis, and cancer
Yu, F.-X., Zhao, B., & Guan, K.-L. (2015) · Cell · doi:10.1016/j.cell.2015.10.044 · Cited by 2,206
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017
Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity
Jackson, A. L., Burchard, J., Schelter, J. M., Chau, B. N., Cleary, M. A., Lim, L. P., & Linsley, P. S. (2006) · RNA · doi:10.1261/rna.25706 · Cited by 979
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
DuPage, M. J. P., Dooley, A. L., & Jacks, T. (2009) · Nature Protocols · doi:10.1038/nprot.2009.95 · Cited by 873

Show all 36 references

Sorted by citations

Items 101–200 of 206

KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma
Choi, S. M., Andea, A. A., Wang, M., Behdad, A., Shao, L., Zhang, Y., Lu, X., Dittmann, D., Castro, J., Chen, Y.-H., et al. (2018) · Diagnostic Pathology · doi:10.1186/s13000-018-0758-0 · Cited by 20
RAE1 mediated ZEB1 expression promotes epithelial–mesenchymal transition in breast cancer
Oh, J. H., Lee, J., Yu, S., Cho, Y., Hur, S., Nam, K. T., & Kim, M. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-39574-8 · Cited by 19
NEDD4 protects vascular endothelial cells against Angiotensin II-induced cell death via enhancement of XPO1-mediated nuclear export
Xu, J., Sheng, Z.-Y., Li, F., Wang, S., Yuan, Y., Wang, M., & Yu, Z. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.111505 · Cited by 18
Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer
Gravina, G. L., Mancini, A., Colapietro, A., Marampon, F., Sferra, R., Pompili, S., Biordi, L. A., Iorio, R., Flati, V., Argueta, C. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22760 · Cited by 18
Self-citation
Targeting dihydroorotate dehydrogenase in acute myeloid leukemia
Zeng, Z., & Konopleva, M. Y. (2018) · Haematologica · doi:10.3324/haematol.2018.197806 · Cited by 18
Identification of Prognostic and Chemopredictive microRNAs for Non-Small-Cell Lung Cancer by Integrating SEER-Medicare Data
Ye, Q., Putila, J. J., Raese, R. A., Dong, C., Qian, Y. R., Dowlati, A., & Guo, N. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147658 · Cited by 17
The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma
Sellin, M., Berg, S. A., Hagen, P. A., & Zhang, J. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101448 · Cited by 17
Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects
Li, S., Fu, J., Walker, C. J., Yang, J., Bhutani, D., Chakraborty, R., Mamillapalli, N., Mapara, M. Y., Landesman, Y., & Lentzsch, S. (2023) · Blood Advances · doi:10.1182/bloodadvances.2021006638 · Cited by 17
Self-citation
Sex-Biased Expression of Pharmacogenes across Human Tissues
Idda, M. L., Campesi, I., Fiorito, G., Vecchietti, A., Urru, S. A. M., Solinas, G., Franconi, F., & Floris, M. (2021) · Biomolecules · doi:10.3390/biom11081206 · Cited by 17
An update to the CRM1 cargo/NES database NESdb
Fung, H. Y. J., Niesman, A. B., & Chook, Y. M. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e20-11-0694 · Cited by 16
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics
Choo, J. R.-E., Sargsyan, A., Khachatryan, V., Lonardi, S., Pietrantonio, F., Sundar, R., Klempner, S. J., & Janjigian, Y. Y. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01134-1 · Cited by 17
Targeting Mutant KRAS for Anticancer Therapy
Chen, F., Alphonse, M. P., Liu, Y., & Liu, Q. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190902151307 · Cited by 15
Nuclear export of BATF2 enhances colorectal cancer proliferation through binding to CRM1
Zhou, J., Lei, Z., Chen, J., Liao, S., Chen, Y., Liu, C., Huang, S., Li, L., Zhang, Y., Wang, P., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1260 · Cited by 15
Therapeutic targeting of exportin-1 beyond nuclear export
Chen, Y., & Adams, D. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.11.002 · Cited by 14
Autophagy modulates glioblastoma cell sensitivity to Selinexor-mediated XPO1 inhibition
Tang, Y., Sprinzen, L., Terada, Y., Kiang, K. M. Y., Li, C., Zeng, Y., Liu, F., Zhou, H., Liang, X., Zhang, M., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae280 · Cited by 14
Anticancer and therapeutic efficacy of XPO1 inhibition in pancreatic ductal adenocarcinoma through DNA damage and modulation of miR-193b/KRAS/LAMC2/ERK/AKT signaling cascade
Kirtonia, A., Pandya, G., Singh, A. P., Kumari, R., Singh, B., Kapoor, S., Khattar, E., Pandey, A. K., & Garg, M. (2025) · Life Sciences · doi:10.1016/j.lfs.2024.123364 · Cited by 14
Inhibition of exportin-1 function results in rapid cell cycle-associated DNA damage in cancer cells
Burke, R. T., Marcus, J. M., & Orth, J. D. (2017) · Oncotarget · doi:10.18632/oncotarget.17063 · Cited by 14
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)
Nagasaka, M., Asad, M., Hallak, M. N. A., Uddin, M. H., Sukari, A. W., Baca, Y., Xiu, J., Magee, D., Mamdani, H. M., Uprety, D., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.08.010 · Cited by 14
The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target—a narrative review
Spagnuolo, A., Maione, P., & Gridelli, C. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-948 · Cited by 15
Megakaryocyte modification of platelets in thrombocytopenia
Roweth, H. G., Parvin, S., & Machlus, K. R. (2018) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000451 · Cited by 14
Selinexor: A First-in-Class SINE Compound for Treatment of Relapsed Refractory Multiple Myeloma
Richard, S., Richter, J. R., & Jagannath, S. (2020) · Future Oncology · doi:10.2217/fon-2020-0054 · Cited by 14
Follistatin Like 5 (FSTL5) inhibits epithelial to mesenchymal transition in hepatocellular carcinoma
Zhang, D., Lei, J., Sun, W., Wang, D., & Lü, Z. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000847 · Cited by 13
IκBα Nuclear Export Enables 4-1BB–Induced cRel Activation and IL-2 Production to Promote CD8 T Cell Immunity
Lisiero, D. N., Zhang, C., Tejera, M. M., Neldner, B., Warrick, J. W., Wuerzberger‐Davis, S. M., Hoffmann, A., Suresh, M., & Miyamoto, S. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000039 · Cited by 13
Synthetic Vulnerabilities in the KRAS Pathway
Román, M., Hwang, E. E., & Sweet-Cordero, A. (2022) · Cancers · doi:10.3390/cancers14122837 · Cited by 14
Reactivating Hippo by drug compounds to suppress gastric cancer and enhance chemotherapy sensitivity
Cao, Z., Hou, Y., Zhao, Z., Zhang, H., Tian, L., Zhang, Y., Dong, C., Guo, F., Tan, L., Han, Y., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107311 · Cited by 12
Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition
Chaudhry, S., Beckedorff, F., Jasdanwala, S. S., Totiger, T. M., Affer, M., Lawal, A. E., Montoya, S., Tamiro, F., Tonini, O., Chirino, A., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02328-1 · Cited by 11
A Proteomic Approach Identifies Isoform-Specific and Nucleotide-Dependent RAS Interactions
Miller, S. P., Maio, G. E., Zhang, X., Soto, F. S. B., Zhu, J., Ramirez, S. Z., & Lin, H. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100268 · Cited by 11
Prognostic value and therapeutic targeting of XPO1 in chronic lymphocytic leukemia
Xu, Z., Pan, B., Miao, Y., Li, Y., Qin, S., Liang, J., Kong, Y., Zhang, X., Tang, J., Xia, Y., et al. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01003-6 · Cited by 10
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non–small cell lung cancer
Altan, M., Tu, J. C., Milton, D. R., Yilmaz, B., Tian, Y., Fossella, F. V., Mott, F. E., Blumenschein, G. R., Stephen, B., Karp, D. D., et al. (2023) · Cancer · doi:10.1002/cncr.34820 · Cited by 9
Discovery and biological evaluation of a small‐molecule inhibitor of CRM1 that suppresses the growth of triple‐negative breast cancer cells
Gao, J., Chu, P., Liu, C., Sun, Z., Liu, Q., & Yang, Y. (2021) · Traffic · doi:10.1111/tra.12802 · Cited by 9
A cholesterogenic gene signature for predicting the prognosis of young breast cancer patients
Li, X., Zhou, C., Qiu, C., Li, W., Yu, Q., Huang, H., Zhang, Y., Zhang, X., Ren, L., Huang, X., et al. (2022) · PeerJ · doi:10.7717/peerj.13922 · Cited by 9
A Genome-wide Functional Signature Ontology Map and Applications to Natural Product Mechanism of Action Discovery
McMillan, E. A., Kwon, G., Clemenceau, J. R. V., Fisher, K. W., Vaden, R. M., Shaikh, A. F., Neilsen, B. K., Kelly, D., Potts, M. B., Sung, Y.-J., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.07.008 · Cited by 9
Self-citation
A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients
Zhu, Z., Yang, L., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07552-3 · Cited by 8
Hydrocortisone alleviates sepsis-induced acute kidney injury through HSF-1-mediated transcriptional suppression of XPO1
Jin, L., Liao, W., Zhou, X., Wang, Y., & Qian, J. (2022) · Tissue and Cell · doi:10.1016/j.tice.2022.101915 · Cited by 8
Miz1 promotes KRAS-driven lung tumorigenesis by repressing the protocadherin Pcdh10
Yang, J., Hou, C., Wang, H., Perez, E. A., Do-Umehara, H. C., Dong, H., Arunagiri, V., Tong, F., Scoyk, M. M. V., Cho, M., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216025 · Cited by 8
Identification of Pharmacologically Tractable Protein Complexes in Cancer Using the R-Based Network Clustering and Visualization Program MCODER
Kwon, G., Kim, H., & Kim, H. S. (2017) · BioMed Research International · doi:10.1155/2017/1016305 · Cited by 8
Self-citation
Up-regulated FSTL5 inhibits invasion of hepatocellular carcinoma through the Wnt/β-catenin/YAP pathway.
Zhang, D., Sun, W., Ma, X., Zhang, P., Wu, W., Wu, H., Zhou, S., & Lü, Z. (2017) · PubMed Central · Cited by 8
Determination of the migration effect and molecular docking of verteporfin in different subtypes of breast cancer cells
Wei, C., & Li, X. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11482 · Cited by 8
Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer
Zhao, J., Wang, L., Zhou, A., Wen, S., Fang, W., Zhang, L., Duan, J., Bai, H., Zhong, J., Wan, R., et al. (2024) · Med · doi:10.1016/j.medj.2024.04.011 · Cited by 7
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS -Mutant Non–Small Cell Lung Cancer
von Itzstein, M. S., Burns, T. F., Dowell, J. E., Horn, L., Camidge, D. R., York, S. J., Eaton, K. D., Kyle, K., Fattah, F. J., Liu, J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1722 · Cited by 7
Homeostatic regulation of nucleoporins is a central driver of nuclear pore biogenesis
Sakuma, S., Raı́ces, M., Zhu, E. Y. S., Mamriev, D., Fisher, C. I., Heynen‐Genel, S., & D’Angelo, M. A. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115468 · Cited by 7
Cocktail hepatocarcinoma therapy by a super-assembled nano-pill targeting XPO1 and ATR synergistically
Gong, L., Lu, Y., Wang, J., Li, X., Zhao, J., Chen, Y., Ma, R., Ma, J., Liu, T., & Han, S. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.04.017 · Cited by 7
Yes‐associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1 ‐rearranged lung cancer
Yamazoe, M., Ozasa, H., Tsuji, T., Funazo, T. Y., Yoshida, H., Hashimoto, K., Hosoya, K., Ogimoto, T., Ajimizu, H., Yoshida, H., et al. (2022) · Cancer Science · doi:10.1111/cas.15622 · Cited by 7
Gene alterations in the nuclear transport receptor superfamily: A study of head and neck cancer
Nguyen, P. T., Shimojukkoku, Y., Kajiya, Y., Oku, Y., Tomishima, A., Shima, K., & Sasahira, T. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300446 · Cited by 6
Closing the door on KRAS-mutant lung cancer
Cully, M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.216 · Cited by 6
The nuclear export protein XPO1 provides a peptide ligand for natural killer cells
Blunt, M. D., Fisher, H., Schittenhelm, R. B., Mbiribindi, B., Fulton, R., Khan, S. A., España‐Serrano, L., Graham, L. V., Bastidas-Legarda, L. Y., Burns, D., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado6566 · Cited by 6
Selinexor as a Therapeutic Target: Advances in Non-small Cell and Small Cell Lung Cancer Treatment Strategies
Zheng, B., Zhang, W., Xie, S., Han, Y., Liu, G., Liu, Y., Gao, M., Wang, S., & Liu, Q. (2024) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/0115748928322627241016120142 · Cited by 5
Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide
Otte, K., Zhao, K., Braun, M., Neubauer, A., Raifer, H., Helmprobst, F., Barrera, F. O., Nimsky, C., Bartsch, J. W., & Rusch, T. (2022) · Biomedicines · doi:10.3390/biomedicines10092145 · Cited by 5
Nuclear Export of mRNAs with Disease Pathogenesis and Therapeutic Implications
Guha, S., Barman, P., Manawa, A., & Bhaumik, S. R. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_17 · Cited by 5
RAS: Circuitry and therapeutic targeting
Singh, G., Thakur, N., & Kumar, U. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110505 · Cited by 6
The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures
Ferrara, M. G., Stefani, A., Pilotto, S., Carbone, C., Vita, E., Salvatore, M. D., D’Argento, E., Sparagna, I., Monaca, F., Valente, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.792385 · Cited by 4
Coptisine inhibits the malignancy of bladder carcinoma cells and regulates XPO1 expression
Li, J., & Liu, X. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14291 · Cited by 4
Overcoming Tyrosine Kinase Inhibitor Resistance in Transformed Cell Harboring SEPT9-ABL1 Chimeric Fusion Protein
Kawai, H., Matsushita, H., Suzuki, R., Kitamura, Y., Ogawa, Y., Kawada, H., & Ando, K. (2019) · Neoplasia · doi:10.1016/j.neo.2019.06.001 · Cited by 4
Mechanistic models position ceritinib as a nuclear integrity disrupting therapy in pediatric liver tumors
Demir, S., Keßler, T., Hotes, A., Häberle, B., Hiyama, E., Hishiki, T., Indersie, É., Branchereau, S., Vokuhl, C., Dorel, M., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03535-z · Cited by 3
KRAS Addiction Promotes Cancer Cell Adaptation in Harsh Microenvironment Through Macropinocytosis
Seguin, L. (2022) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-94004-1_10 · Cited by 3
Nuclear Transport Inhibitors
London, C. A. (2023) · CABI eBooks · doi:10.1079/9781789245820.0007 · Cited by 3
Infiltrating characteristics and prognostic value of tertiary lymphoid structures in resected gastric neuroendocrine neoplasm patients
Cai, D., Wang, X., Yu, H., Bai, C., Mao, Y., Liang, M., Xia, X., Liu, S., Wang, M., Lu, X., et al. (2024) · Clinical & Translational Immunology · doi:10.1002/cti2.1489 · Cited by 3
XPO-1 targeting in chronic lymphocytic leukemia: is there potential for therapeutic strategy?
Maher, N., & Gaïdano, G. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2589808 · Cited by 3
Protein-RNA interaction dynamics reveal key regulators of oncogenic KRAS-driven cancers
Ban, K.-Y., Na, Y., Song, J., Kim, J., & Kim, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-78333-2 · Cited by 2
Self-citation
KRAS inhibitors in drug resistance and potential for combination therapy
Rathod, L. S., Sakle, N. S., & Mokale, S. N. (2024) · Tumori Journal · doi:10.1177/03008916241289206 · Cited by 3
Mobilization of nuclear antiviral factors by exportin XPO1 via the actin network inhibits RNA virus replication
Sun, B., Wu, C., González, P. A., & Nagy, P. D. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1012841 · Cited by 2
Exportin 1 inhibitor KPT‑330 reverses oxaliplatin resistance via p53 nuclear retention in colorectal cancer
Lai, C., Jia, X., Chen, Y., Chen, K., Wang, F., Zhang, Q., Xiang, X., Chen, Z., Xu, L., & Dai, S. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5675 · Cited by 2
Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer
Marco, M. V. D., Gasparetto, A., Chiarle, R., & Voena, C. (2025) · Cells · doi:10.3390/cells14241991 · Cited by 2
Trapping Colorectal Cancer Into a Dead-end
Clemons, N. J., & Phillips, W. A. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.03.046 · Cited by 2
A Local-Network Guided Linear Discriminant Analysis for Classifying Lung Cancer Subtypes using Individual Genome-Wide Methylation Profiles
Li, Y. (2019) · Advances in intelligent systems and computing · doi:10.1007/978-3-030-32520-6_50 · Cited by 2
Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition
Lai, L., Brel, V., Sharma, K., Frappier, J., Le-Henanf, N., Vivet, B., Muzet, N., Schell, E., Morales, R., Rooney, E. K., et al. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211008853 · Cited by 2
Balancing the yin and yang of SINE
Pluthero, F. G., & Kahr, W. H. A. (2017) · Blood · doi:10.1182/blood-2017-07-793398 · Cited by 2
Basic science in oncology: year 2016 overview
Имянитов, Е. Н. (2017) · Practical oncology · doi:10.31917/1801085 · Cited by 2
Peptide:MHC dependent activation of natural killer cells through KIR2DS2 generates anti-tumor responsesPreprint
Rettman, P., Blunt, M. D., Mbiribindi, B., Fulton, R., Schittenhelm, R. B., Vallejo, A. F., Bastidas-Legarda, L. Y., Polak, M. E., Ayala, R., Purcell, A. W., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.15.042077 · Cited by 2
Exportin 1/chromosome region maintenance 1 as a therapeutic target for lung cancer
Gao, W. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.02.35 · Cited by 1
Current Advances in Computational biology of Lung Cancer
Pati, P. (2022) · International Journal of Current Science Research and Review · doi:10.47191/ijcsrr/v5-i1-11 · Cited by 1
Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC
Rosell, R., Karachaliou, N., Codony, C., & Ito, M. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.03.20 · Cited by 1
Overcoming the drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancer cell lines
Liu, Z. (2018) · ThinkTech (Texas Tech University)
[Air-conditioning and air-circulation systems in hospitals (author's transl)].
Steuér, W. (1973) · PubMed
Tackling the Moving Mutant Target: Taxifolin Derivatives as Novel Putative E571K Exportin-1 Inhibitors for KRAS-mutant Lung Adenocarcinoma TherapyPreprint
Adigun, T. O., Medayedupin, O. A., Joel, I., Fakolujo, I. Y., Ofeniforo, B., Bankole, F. A., Omoniyi, A. P., Ogunro, O. B., Agunlejika, A., Omoyeni, O. C., et al. (2020) · Preprints.org · doi:10.20944/preprints202012.0797.v1
Ras and Ras Signaling as a Therapeutic Target in Cancer
Sliker, B. H., & Campbell, P. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00006-2
レプトマイシン物語
Yoshida, M. (2018) · KAGAKU TO SEIBUTSU · doi:10.1271/kagakutoseibutsu.56.197
Faculty Opinions recommendation of Tpr regulates the total number of nuclear pore complexes per cell nucleus.
Stewart, M. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734041309.793552289
Synthetic Lethality and Lung Cancer
Huang, J., Qiao, T., & Wang, X. (2022) · Translational bioinformatics · doi:10.1007/978-981-16-7893-6_5
Data from Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy
Quintanal-Villalonga, À., Taniguchi, H., Hao, Y., Chow, A. T., Zhan, Y. A., Chavan, S. S., Uddin, F. Z., Allaj, V., Manoj, P., Shah, N., et al. (2023) · doi:10.1158/0008-5472.c.6513732.v1
Data from Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma
Turner, J. G., Cui, Y., Bauer, A. A., Dawson, J. L., Gomez, J. A., Kim, J., Cubitt, C. L., Nishihori, T., Dalton, W. S., & Sullivan, D. M. (2023) · doi:10.1158/0008-5472.c.6511792.v1
Self-citation
Data from Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
Khan, H. Y., Nagasaka, M., Li, Y., Aboukameel, A., Uddin, M. H., Sexton, R. E., Bannoura, S. F., Mzannar, Y., Hallak, M. N. A., Kim, S. H., et al. (2023) · doi:10.1158/2767-9764.c.6550541
Self-citation
Supplementary Data from Inhibition of Nuclear Pore Complex Formation Selectively Induces Cancer Cell Death
Sakuma, S., Raı́ces, M., Borlido, J., Guglielmi, V., Zhu, E. Y. S., & D’Angelo, M. A. (2023) · doi:10.1158/2159-8290.22535729
Involvement of Exportin 1 Mediated c-Myc and Cullin 4A Signaling in Apoptotic Effect of Fisetin in Non-small Cell Lung Cancer Cells
Kim, J. Y., Lee, H., Park, J. E., Sim, D. Y., Lee, H. J., Ahn, C., Park, S., Shim, B., Kim, B., & Kim, S. (2023) · Journal of Oncology Research and Therapy · doi:10.29011/2574-710x.10169
Self-citation
Additional file 8 of A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212775
Additional file 7 of A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212772
Additional file 9 of A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212778
Additional file 10 of A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212751
Additional file 6 of A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients
Zhu, Z., Yang, L., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212769
High XPO1 Expression can Stratify Gastric Cancer Patients with Poor Clinical Outcome
(2024) · Cancer Studies and Therapeutics · doi:10.31038/cst.2024921
Exporting nuclear export inhibitors from hematologic to solid tumour malignancies
Chirino, A., Maye, A., & Taylor, J. (2024) · Clinical and Translational Discovery · doi:10.1002/ctd2.356
Therapeutic Targeting of KRAS Oncogene in Pancreatic Ductal Adenocarcinoma (PDAC)
Song, J. J. (2024) · Journal of Student Research · doi:10.47611/jsrhs.v13i1.6375
Tackling the Moving Mutant Target: Taxifolin Derivatives as Novel Putative E571K Exportin-1 Inhibitors for KRAS-mutant Lung Adenocarcinoma
Adigun, T. O., Alejolowo, O. O., Sulaiman, F. A., Oluwadare, I. A., Ogunro, O. B., Akinduko, A., Evbuomwan, I. O., Agunlejika, A., Nwonuma, C. O., & Rotimi, D. E. (2024) · International Conference on Science, Engineering and Business for Driving Sustainable Development Goals (SEB4SDG) · doi:10.1109/seb4sdg60871.2024.10630422
Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinomaPreprint
Khan, H. Y., Hallak, M. N. A., Aboukameel, A., Bannoura, S. F., Uddin, M. H., Aboukameel, A. A., Alkan, F. K., Çağlayan, A. B., Alkan, H. K., Bao, B., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.21.689857
Additional file 3 of A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212760
Additional file 1 of A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212754
Additional file 5 of A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212766
Additional file 4 of A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212763
Additional file 2 of A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212757
Étude des anomalies de XPO1 dans les lymphomes B
Miloudi, H. (2020) · theses.fr (ABES) · doi:10.70675/bed6d2d2zab43z4363z8153zaf694852437a

Authors: Kim, J., McMillan, E., Kim, H. S., Venkateswaran, N., Makkar, G., Rodriguez-Canales, J., Villalobos, P., Neggers, J. E., Mendiratta, S., Wei, S., Landesman, Y., Senapedis, W., Baloglu, E., Chow, C.-W. B., Frink, R. E., Gao, B., Roth, M., Minna, J. D., Daelemans, D., Wistuba, I. I., Posner, B. A., Scaglioni, P. P., & White, M. A.
Affiliations: Yonsei University (KR)
The University of Texas MD Anderson Cancer Center (US)
KU Leuven (BE)
Karyopharm Therapeutics (United States) (US)
Corresponding author: White, Michael A.
ORCID: Kim, Jimi
McMillan, Elizabeth
Kim, Hyun Seok
Venkateswaran, Niranjan
Neggers, Jasper Edgar
Mendiratta, Saurabh
Wei, Shuguang
Landesman, Yosef
Senapedis, William
Baloglu, Erkan
Gao, Boning
Roth, Michael
Minna, John D.
Daelemans, Dirk
Wistuba, Ignacio I.
Posner, Bruce A.
Scaglioni, Pier Paolo
White, Michael A.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2016-09-28
Volume: 538
Issue: 7623
Pages: 114-117
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature19771
PMC: PMC5161658
OpenAlex: W2526506448
Cited by: 202
References: 36
Citations by year: 2026: 6 · 2025: 11 · 2024: 22 · 2023: 13 · 2022: 23 · 2021: 18 · 2020: 27 · 2019: 23 · 2018: 32 · 2017: 25 · 2016: 1
FWCI: 14.04
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
RePEc: Research Papers in Economics (submittedVersion)
Lirias (KU Leuven) (submittedVersion)
Funders: Cancer Prevention and Research Institute of Texas
National Cancer Institute (P50CA070907, U01CA176284, RC2CA148225)
National Institute of General Medical Sciences (T32GM008203)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Structure and Function
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords: CRM1, nuclear export, KRAS-mutant lung cancer, non-small cell lung cancer, synthetic lethality, NF-κB, IκBα, YAP, Hippo signaling pathway, verteporfin, drug resistance, RNAi screen, cell lines, KRAS inhibitors
MeSH terms: NF-KappaB Inhibitor alpha, Verteporfin, Hippo Signaling Pathway, YAP-Signaling Proteins, TEA Domain Transcription Factors, Exportin 1 Protein, Animals, Carcinoma, Non-Small-Cell Lung, Cell Nucleus, Cell Survival, DNA-Binding Proteins, Female, Genes, Lethal, Humans, Lung Neoplasms, Mutation, Nuclear Proteins, Phosphoproteins, Porphyrins, Transcription Factors, Signal Transduction, Proto-Oncogene Proteins p21(ras), NF-kappa B, Protein Serine-Threonine Kinases, Receptors, Cytoplasmic and Nuclear, Active Transport, Cell Nucleus, Xenograft Model Antitumor Assays, Karyopherins, RNA Interference, RNA, Small Interfering, Follistatin-Related Proteins, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks